Radiopharmaceuticals and Nanotechnology: From Diagnostics to Theranostic Applications
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Nanomedicine and Nanotechnology".
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 10338
Special Issue Editor
Interests: cardiovascular imaging; angiogenesis-targeting theranostics; molecular imaging; functional imaging; vectorized radiotherapy; radiochemistry;
Special Issue Information
Dear Colleagues,
Much can be found in the literature about nanotechnology and health. In the field of nuclear medicine and radiopharmaceuticals in the 2000s, developing and radiolabeling a nanomaterial was highly innovative in itself, even if its in vivo biodistribution was disseminated to… all the main organs of the body! In the 2010s, nanotechnology became the focus of the whole community, with two “holy grails”: enhancing the specificity and lowering the toxicity of radiopharmaceuticals for tumor diagnostics and theranostics. From a methodological point of view, harmonization and collaboration have always represented the key for translating research developments from bench to bedside. However, the numerous proofs of concept and developments published in the past 10 years have raised a couple of questions that now need to be answered: how many nanoradiopharmaceuticals have been developed and published, with encouraging preclinical results but absolutely no clinical output? We hear that nanoradiopharmaceuticals are the future of nuclear medicine, but why does it take so long for a nanoradiopharmaceutical to find its place in clinical trials? Is toxicity an insurmountable hindrance? Have we used accurate preclinical models? Have we considered tissue heterogeneity when applicable? Have we focused on the right clinical indications? Is there still a place for such cutting-edge nanotechnologies in diagnostics and theranostics? We hope this Special Issue will inspire transdisciplinary teams to join their best forces, i.e., specialized engineers, (radio)pharmacists, (radio)chemists, (radio)physicists, pharmacokinetics specialists and nuclear MDs, because that is precisely what this topic needs. Let us zoom in together to the nanoscale and take a picture of what tomorrow’s radiopharmaceuticals might look like.
Dr. Philippe Garrigue
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Nanotechnology
- Nanosystem
- PET
- SPECT
- Radiopharmaceuticals
- Radiotherapy
- Theranostics
